Organon & Co. (OGN) Presents at Piper Sandler 34th Annual Healthcare Conference

Nov. 29, 2022 2:26 PM ETOrganon & Co. (OGN)
SA Transcripts profile picture
SA Transcripts
133.8K Followers

Organon & Co. (NYSE:OGN) Piper Sandler 34th Annual Healthcare Conference November 29, 2022 9:00 AM ET

Company Participants

Kevin Ali - Chief Executive Officer

Matt Walsh - Chief Financial Officer

Conference Call Participants

David Amsellem - Piper Sandler

David Amsellem

Okay. Good morning. Welcome to the 34th Annual Piper Sandler Healthcare Conference. I'm David Amsellem from the specialty pharma team, Eric [ph] Piper. Our next company Fireside Chat is Organon and we're delighted to have Kevin Ali, CEO and Matt Walsh, CFO. Thanks so much for joining us and lots to talk about. So let's just dive right in, if that's okay.

Kevin Ali

Sure.

Question-and-Answer Session

Q - David Amsellem

So I like to start off with a couple of high level questions. And the first is, as we move into 2023 -- and I know you get this a lot, what are your biggest priorities in terms of BD M&A? More specifically is the goal to bolster the pipeline or at commercial stage assets or mix of both? And the reason I started there is because it's something that you've talked about a lot on -- in previous conferences and previous calls, obviously lots to talk about with the business, but I think that would be a good place to start.

Kevin Ali

Sure. Well, we said it a number of times David that we're taking kind of a balanced approach to BD where you know we're focused on being a leader in women's health as a focus of the vision for the company. And so we've done some -- we've actually done seven deals since the start of this company a little over 18 months ago or 18 months ago. And so the focus is some early stage assets that have absolutely blockbuster potential, which I'm sure we'll talk about them in a few

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.